Filing Details

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

Design Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

25056L 103

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

*	The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 25056L 103		13G		Page 2 of 5 Pages

 

1.		Names of Reporting Persons   Aseem Z. Ansari, Ph.D.
2.		Check the Appropriate Box if a Member of a Group (see instructions) (a)  ☐        (b)  ☐
3.		SEC USE ONLY
4.		Citizenship or Place of Organization   United States

Number of Shares Beneficially Owned by Each Reporting Person With:				5.		Sole Voting Power   7,668,711
				6.		Shared Voting Power   0
				7.		Sole Dispositive Power   7,668,711
				8.		Shared Dispositive Power   0

9.		Aggregate Amount Beneficially Owned by Each Reporting Person   7,668,711
10.		Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)   ☐
11.		Percent of Class Represented by Amount in Row 9   13.8%(1)
12.		Type of Reporting Person (see instructions)   IN

 

(1)	The percentage is calculated based on 55,662,501 shares of Common Stock outstanding as of November 5, 2021, as reported in the Issuers Quarterly Report on Form 10-Q filed on November 5, 2021.

CUSIP No. 25056L 103		13G		Page 3 of 5 Pages

 

Item 1(a).				Name of Issuer: Design Therapeutics, Inc., a Delaware corporation
Item 1(b).				Address of Issuers Principal Executive Offices: 6005 Hidden Valley Road, Suite 110 Carlsbad, CA 92011
Item 2(a).				Name of Person Filing: Aseem Z. Ansari, Ph.D.
Item 2(b).				Address of Principal Business Office or, if none, Residence:   Department of Chemical Biology & Therapeutics Mailstop #1000 262 Danny Thomas Pl. Memphis, TN 38105
Item 2(c).				Citizenship: USA
Item 2(d).				Title of Class of Securities: Common Stock
Item 2(e).				CUSIP Number: 25056L 103
Item 3.				Not applicable
Item 4.				Ownership
(a)		Amount Beneficially Owned: 7,668,711 shares of Common Stock
(b)		Percent of Class: 13.8%
(c)		Number of shares as to which the person has:
		(i)  Sole power to vote or to direct the vote: 7,668,711
		(ii)  Shared power to vote or to direct the vote: 0
		(iii)   Sole power to dispose or to direct the disposition of: 7,668,711
		(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.		Ownership of Five Percent or Less of a Class
		Not applicable
Item 6.		Ownership of More than Five Percent on Behalf of Another Person
		Not applicable
Item 7.		Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
		Not applicable

Page 3 of 4 pages

CUSIP No. 25056L 103		13G		Page 4 of 5 Pages

 

Item 8.		Identification and Classification of Members of the Group
		Not applicable
Item 9.		Notice of Dissolution of a Group
		Not applicable
Item 10.		Certification
		Not applicable

CUSIP No. 25056L 103				Page 5 of 5 Pages

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representatives authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to be sent.

Attention:     Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)